Forsta AP Fonden buys 137,100 shares of Royalty Pharma plc (NASDAQ:RPRX)

Forsta AP Fonden boosted its stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 138.8% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 235,900 shares of the biopharmaceutical company’s stock after purchasing an additional 137,100 shares during the quarter. Forsta AP Fonden’s holdings in Royalty Pharma were worth $6,221,000 at the end of the most recent quarter.

Several other large investors have added to or reduced their stakes in RPRX. Ballentine Partners LLC grew its position in shares of Royalty Pharma by 3.3% in the first quarter. Ballentine Partners LLC now owns 12,541 shares of the biopharmaceutical company’s stock worth $381,000 after purchasing an additional 406 shares in the last quarter. NEOS Investment Management LLC raised its position in shares of Royalty Pharma by 5.0% in the 4th quarter. NEOS Investment Management LLC now owns 8,589 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 409 shares in the last quarter . EverSource Wealth Advisors LLC grew its position in shares of Royalty Pharma by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,807 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 802 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. raised its position in shares of Royalty Pharma by 10.8% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 9,097 shares of the biopharmaceutical company’s stock worth $276,000 after buying an additional 887 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in shares of Royalty Pharma by 172.5% in the first quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 1,037 shares during the last quarter. Institutional investors own 54.35% of the company’s shares.

Changes in Analyst Ratings

Several equities analysts have recently issued reports on the company. UBS Group lowered Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 target price for the company. in a research report on Monday, June 3rd. Morgan Stanley boosted their price target on Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research report on Thursday, July 11th. Goldman Sachs Group boosted their price target on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Finally, StockNews.com lowered Royalty Pharma from a “buy” rating to a “hold” rating in a research report on Monday, September 9th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Moderate Buy” and an average target price of $42.00, based on data from MarketBeat.

Check out the latest stock analysis on Royalty Pharma

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX opened at $27.72 on Friday. Royalty Pharma plc has a fifty-two week low of $25.20 and a fifty-two week high of $31.66. The company has a 50 day simple moving average of $27.80 and a two hundred day simple moving average of $28.06. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35, and a current ratio of 9.35. The firm has a market cap of $16.56 billion, a price-to-earnings ratio of 20.69, a price-to-earnings-growth ratio of 4.10 and a beta of 0.46.

Royalty Pharma (NASDAQ:RPRX – Get Your Free Report ) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.01. The business had revenue of $537.00 million during the quarter, compared to the consensus estimate of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same period in the previous year, the company posted EPS of $0.85. On average, analysts expect that Royalty Pharma plc will post 4.04 earnings per share for the current year.

Royalty Pharma announces dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 13th. Shareholders of record on Friday, August 16th were given a dividend of $0.21 per share. The ex-dividend date of this dividend was Friday, August 16. This represents a dividend of $0.84 on an annualized basis and a dividend yield of 3.03%. Royalty Pharma’s dividend payout ratio is currently 62.69%.

About Royalty Pharma

(Free Report)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a financier of innovation in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation and acquisition of royalties for various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and non-profit organizations, small and mid-sized biotech companies and pharmaceutical companies.

Featured stories

Want to see what other hedge funds own RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma plc (NASDAQ:RPRX – Free Report).

Get news and reviews for Royalty Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Royalty Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.